Braftovi
What is Braftovi (Encorafenib)?
Related Clinical Trials
Summary: The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study...
Summary: Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urgent that the investigators identify effective therapies. ENCEFALO is a Phase II, single arm, multicentre clinical trial ...
Summary: This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003...
Related Latest Advances
Brand Information
- New Primary Malignancies
- Tumor Promotion in BRAF Wild-Type Tumors
- Cardiomyopathy
- Hepatotoxicity
- Hemorrhage
- Uveitis
- QT Prolongation
- Embryo-Fetal Toxicity
- Risks Associated with BRAFTOVI as a Single Agent
- Risks Associated with Combination Treatment






